Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar to Host Investor and Analyst R&D Day in New York City Apr 10, 2012 Nektar Doses First Subjects in Phase 1 Clinical Study Evaluating NKTR-192, a New Short-Acting Opioid Molecule for the Treatment of Acute Pain Apr 02, 2012 Nektar Reports that Partner Affymax Has Announced FDA Approval of OMONTYS® (Peginesatide) Injection for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis Mar 28, 2012 Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay Mar 20, 2012 Nektar Therapeutics Announces Webcast of Presentation at the 32nd Annual Cowen and Company Healthcare Conference in Boston Mar 02, 2012 Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results Feb 29, 2012 Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million Feb 29, 2012 Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting Feb 27, 2012 Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2011 on Wednesday, February 29, 2012, After Close of U.S.-Based Financial Markets Feb 24, 2012 Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Jan 04, 2012 Pagination First page « first Previous page ‹ previous … Page 30 Page 31 Page 32 Page 33 Current page 34 Page 35 Page 36 Page 37 Page 38 … Next page next › Last page last »